Metabolic abnormalities and recurrence in high-risk urinary stone formers: A prospective cohort study.
- 1Department of Urology, SANKO University Faculty of Medicine, Gaziantep, Turkey.
- 2Department of Urology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey.
Abstract
Introduction
High-risk urinary stone formers are advised to undergo comprehensive metabolic assessment and targeted prophylaxis; however, recurrence outcomes under guideline-based prevention programs remain uncertain.Material and methods
We conducted a prospective, single-center observational cohort study including adult high-risk stone formers rendered stone-free after surgical/endourological treatment. All patients underwent standardized blood tests, 24-hour urine evaluation, and stone composition analysis. Patients with at least one metabolic abnormality received risk factor-specific therapy, whereas those without abnormalities received non-specific measures and lifestyle counseling. Recurrence was defined as a newly detected stone ≥3 mm on follow-up imaging.Results
Sixty-four patients were included (mean age 33.47 ±10.32 years; 60.9% male). At least one metabolic abnormality was identified in 42 patients (65.6%); hypocitraturia was the most frequent abnormality (53.1%). Metabolic syndrome was present in 16 patients (25.0%) and was more common among patients with metabolic abnormalities (33.3% vs 9.1%; p = 0.033). Over a mean follow-up of 24.5 months, recurrence occurred in 10 patients (15.6%). Recurrence rates were 16.7% (7/42) in the targeted-therapy group and 13.6% (3/22) in the non-specific group (p = 0.749), corresponding to a relative risk of 1.22 (95% confidence interval 0.35-4.27). Among patients who experienced recurrence (n = 10), the time to recurrence was 11.8 ±5.69 months (median 12.5 months; range 4-19 months).Conclusions
In this high-risk cohort, metabolic abnormalities were common, and metabolic syndrome clustered with metabolic risk factors. Between-group recurrence estimates were imprecise; larger studies with robust adjustment for baseline risk and adherence are needed. The observational, risk-stratified design precludes causal inference regarding the effectiveness of targeted medical metaphylaxis.
Related
- High-grade inflammation, metabolic abnormalities, and incident type 2 diabetes: a dynamic matched prospective cohort study
- Urinary dual-site proenkephalin (PENK) methylation testing for detection of high-grade or invasive recurrence during surveillance of non-muscle-invasive bladder cancer
- Urinary Extracellular Vesicle–Associated EphA2 Predicts Intravesical Recurrence in Bladder Cancer
- Life-Threatening Ventricular Tachycardia and Transient Brugada-Like Electrocardiographic Abnormalities Caused by Severe Hyperkalemia Due to Urinary Retention in a 55-Year-Old Man.
- Prevalence of Mild Autonomous Cortisol Secretion Among Patients With Adrenal Incidentaloma and Its Association With Metabolic Abnormalities: A Hospital-Based, Analytical, Cross-Sectional Study
BibTeX
@article{tufekci2026metabolic,
title = {{Metabolic abnormalities and recurrence in high-risk urinary stone formers: A prospective cohort study.}},
author = {Ahmet Tüfekçi and İlker Seçkiner},
journal = {Central European journal of urology},
year = {2026},
month = jul,
doi = {10.5173/ceju.2025.0316},
url = {https://europepmc.org/article/MED/42904082},
note = {CC BY-NC-SA},
}
RIS
TY - JOUR
TI - Metabolic abnormalities and recurrence in high-risk urinary stone formers: A prospective cohort study.
AU - Ahmet Tüfekçi
AU - İlker Seçkiner
PY - 2026
DA - 2026/07/17
JO - Central European journal of urology
DO - 10.5173/ceju.2025.0316
UR - https://europepmc.org/article/MED/42904082
AB - Introduction High-risk urinary stone formers are advised to undergo comprehensive metabolic assessment and targeted prophylaxis; however, recurrence outcomes under guideline-based prevention programs remain uncertain.Material and methods We conducted a prospective, single-center observational cohort study including adult high-risk stone formers rendered stone-free after surgical/endourological treatment. All patients underwent standardized blood tests, 24-hour urine evaluation, and stone composition analysis. Patients with at least one metabolic abnormality received risk factor-specific therapy, whereas those without abnormalities received non-specific measures and lifestyle counseling. Recurrence was defined as a newly detected stone ≥3 mm on follow-up imaging.Results Sixty-four patients were included (mean age 33.47 ±10.32 years; 60.9% male). At least one metabolic abnormality was identified in 42 patients (65.6%); hypocitraturia was the most frequent abnormality (53.1%). Metabolic syndrome was present in 16 patients (25.0%) and was more common among patients with metabolic abnormalities (33.3% vs 9.1%; p = 0.033). Over a mean follow-up of 24.5 months, recurrence occurred in 10 patients (15.6%). Recurrence rates were 16.7% (7/42) in the targeted-therapy group and 13.6% (3/22) in the non-specific group (p = 0.749), corresponding to a relative risk of 1.22 (95% confidence interval 0.35-4.27). Among patients who experienced recurrence (n = 10), the time to recurrence was 11.8 ±5.69 months (median 12.5 months; range 4-19 months).Conclusions In this high-risk cohort, metabolic abnormalities were common, and metabolic syndrome clustered with metabolic risk factors. Between-group recurrence estimates were imprecise; larger studies with robust adjustment for baseline risk and adherence are needed. The observational, risk-stratified design precludes causal inference regarding the effectiveness of targeted medical metaphylaxis.
SN - 2080-4806
SN - 2080-4873
ER -